RFK Jr. Moves to Remove GLP-1 Medications from Schedule II: What It Means for Patients

In a move that has sent shockwaves through the weight loss industry, HHS Secretary Robert F. Kennedy Jr. announced plans to remove GLP-1 receptor agonist medications from Schedule II controlled substance classification. If enacted, this policy shift could fundamentally change how these medications are prescribed, priced, and accessed by millions of Americans.

What Was Announced

Secretary Kennedy announced that the Department of Health and Human Services would pursue regulatory action to remove GLP-1 receptor agonists — including semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) — from Schedule II of the Controlled Substances Act. The announcement came as part of a broader initiative to reduce regulatory barriers to medications that Kennedy has characterized as "essential to addressing the obesity epidemic."

The announcement emphasized that the current scheduling creates unnecessary friction for patients and providers, particularly in the telehealth space where prescribing controlled substances involves additional regulatory requirements.

What Is Schedule II?

The Controlled Substances Act categorizes drugs into five schedules based on their potential for abuse, accepted medical use, and safety profile:

• Schedule I: No accepted medical use, high abuse potential (e.g., heroin, LSD)
• Schedule II: Accepted medical use but high abuse potential, may lead to severe dependence (e.g., oxycodone, Adderall)
• Schedule III-V: Decreasing abuse potential
• Non-scheduled: Not considered controlled substances

Schedule II classification imposes strict requirements on prescribing: no refills allowed (each prescription requires a new order), quantity limits, special DEA registration for prescribers, and additional state-level regulations that vary by jurisdiction.

The classification of GLP-1 medications as Schedule II has been controversial since it was implemented. Many physicians and medical organizations have argued that these medications have minimal abuse potential and that the scheduling creates unnecessary barriers to treatment for a disease (obesity) that affects over 40% of American adults.

Why GLP-1 Drugs Were Reclassified

GLP-1 medications were placed on Schedule II following concerns about diversion, off-label cosmetic use, and the rapid expansion of telehealth prescribing. The DEA cited reports of medications being resold, prescribed without adequate medical evaluation, and used by individuals who did not meet clinical criteria for obesity or diabetes treatment.

Critics of the scheduling decision argued that the response was disproportionate — that the medications themselves have essentially no euphoric or addictive properties, and that the real concerns (inappropriate prescribing and diversion) could be addressed through less restrictive regulatory mechanisms.

What Removal Would Mean

If GLP-1 medications are removed from Schedule II (or reclassified to a lower schedule or descheduled entirely), several practical changes would follow:

• Easier prescribing: Physicians would no longer need special DEA waivers or registrations to prescribe these medications
• Refills allowed: Patients could receive refill prescriptions instead of requiring a new prescription each time
• Simplified telehealth: Current restrictions on prescribing controlled substances via telehealth would no longer apply to these medications
• Reduced administrative burden: Pharmacies would have fewer reporting and storage requirements
• Potential for broader access: More providers could prescribe, and patients in underserved areas would have easier access

Impact on Telehealth Prescribing

This is where the impact could be most significant. Current regulations around telehealth prescribing of Schedule II substances require an in-person evaluation in many states, which has created barriers for patients seeking GLP-1 medications through telehealth platforms.

Removing the Schedule II classification would allow telehealth providers to prescribe GLP-1 medications under the same rules as any other non-controlled prescription medication. This would be a major win for patients in rural or underserved areas who rely on telehealth for access to specialized care.

Platforms like Measured, which already specialize in GLP-1 telehealth, would be able to streamline their prescribing process further — potentially reducing the time from consultation to prescription even below the current 1-business-day turnaround.

Impact on Pricing

The scheduling removal could also have downstream effects on pricing. Controlled substance regulations add compliance costs for manufacturers, distributors, and pharmacies. Removing these requirements could modestly reduce costs throughout the supply chain.

More significantly, easier prescribing could increase competition among telehealth providers, driving prices lower through market forces. Patients who currently pay premium prices due to limited provider access could benefit from a broader, more competitive market.

Timeline & Next Steps

The HHS announcement initiates a regulatory process that involves multiple steps:

• Formal rulemaking proposal: HHS will submit a formal proposal to the DEA
• Public comment period: A mandatory period for public input (typically 60-90 days)
• DEA review: The DEA must evaluate the scientific and medical evidence
• Final rule: If approved, a final rule is published with an implementation date

The entire process could take 6-18 months, assuming no major legal challenges. Pharmaceutical industry lobbying — both for and against the change — will likely influence the timeline.

What Patients Should Do Now

For patients currently on GLP-1 medications or considering starting them, the practical advice is straightforward:

• Do not wait. Regulatory changes take time. If you need GLP-1 therapy now, pursue it through current channels.
• Use reputable providers. Regardless of scheduling changes, working with a legitimate telehealth provider ensures proper medical evaluation and monitoring.
• Stay informed. Follow the regulatory process and be prepared to take advantage of simplified access if and when changes take effect.

Providers like Measured already operate within current regulatory requirements and will adapt quickly to any scheduling changes. Their async consultation model and fast prescription turnaround mean patients can start treatment promptly under the existing framework.